PFE Stock: Buy or Sell? Price Target & Forecast

PFE Pfizer Inc As of Jul 29, 2026

$25.25

Large-cap pharma with elevated dividend yield and defensive beta; facing revenue headwinds but maintaining profitability and strong insider buy signals.

Setup: Value / Income Confidence: 68 Horizon: 6–12 months Risk: Medium Category: Large Cap Pharmaceutical

🔒 Trade Plan — entry · target · stop

Entry Zone

$•••–•••

Target

$•••

Stop Loss

$•••

Risk / Reward

•.• : 1

Unlock the exact levels — free →

A free account reveals PFE's entry zone, price target & stop loss. Full 1-week to 1-year price forecasts are included with Pro.

The Thesis

▲ Bull Case

Dividend yield of 6.8% supports income investors; defensive beta (0.28) appeals in uncertain markets; insider buying strong (73 buys vs 26 sells); valuation fair (P/E 19.2x, forward 18.5x) relative to stable margins (12.4% net); current price ~12% below 52-week high suggests pullback opportunity.

▼ Bear Case

Revenue growth sharply negative YoY (-14.8%); EPS declining (-37.1% YoY, -3.5% 5Y); payout ratio unsustainable at 125.8% (paying out more than earnings); quick ratio weak (0.87); no PEG, EPS growth, or ROE data limits growth visibility; sector-wide patent cliff and GLP-1 competition pressuring core products.

Valuation

Fair to Slightly Undervalued — score 72/100

Core multiples (P/E, EV/EBITDA, P/FCF) align with large-cap pharma peers; P/B and net margin slightly cheap. However, the 6.8% dividend yield is elevated for the sector and appears to price in significant risk; unsustainable 125.8% payout ratio likely explains the discount. Valuation is attractive for income, but growth visibility and dividend safety are material concerns.

Technical Levels

Support · $24.94 (Today's low) · $23.11 (52-week low) · $23.50 (Suggested stop-loss)

Resistance · $25.50 (Today's high) · $28.75 (52-week high) · $30.00 (Psychological level + dividend capitalization target)

RSI: Not provided in payload

Financial Health

Score 70/100. Large fortress balance sheet ($143.9B market cap) reduces bankruptcy risk. Current ratio 1.16 is acceptable; quick ratio 0.87 is concerning, suggesting some reliance on inventory conversion or credit lines. No debt-to-equity data limits solvency view. Payout ratio 125.8% is the primary red flag; unsustainable dividend may require correction.

Catalysts

Quarterly Earnings Report	Next scheduled reporting (typically Q2 late July or early August)	High. EPS and revenue trends will clarify whether decline is temporary or structural. Payout ratio guidance critical.
Dividend Announcement / Revision	Typically at board meetings (quarterly); next likely August–September	Very High. Any reduction would confirm sustainability concerns and likely trigger sell-off. Maintenance would provide relief.
Pipeline / Regulatory Updates	Ongoing; FDA approvals typically announced in press releases	Medium-High. New product approvals (especially in high-growth areas) could offset revenue decline and improve payout outlook.
M&A or Divestiture	Unpredictable; pharma M&A is recurrent	Medium. Strategic acquisitions could accelerate growth; divestitures would reduce revenue base but might improve margins.
Industry-wide Patent Cliff or GLP-1 Competition Intensification	2024–2026 (ongoing disclosure)	High. Competitor launches or generic erosion of key franchises could accelerate Pfizer's decline.

Risk Flags

Revenue declining 14.8% YoY; underlying growth concerns and patent expirations likely headwinds.

Payout ratio 125.8% is unsustainable; dividend at risk if earnings do not stabilize or grow.

Quick ratio 0.87 below 1.0; liquidity may tighten if cash burn accelerates.

EPS growth deeply negative (-37.1% YoY); no forward guidance visible in payload.

Insider data strong but limited temporal context; buys may reflect tax-loss harvesting or routine programs.

Recent news includes peer comparisons (JNJ, LLY, ABBV) but no Pfizer-specific catalysts in latest headlines.

See PFE's full trade plan — free

Create a free account to unlock the exact entry, target, and stop — plus run live analysis on any of 5,000+ tickers. No card required.

Unlock PFE free →

More Analyses

NVDA

AAPL

TSLA

MSFT

AMZN

GOOGL

PFE FAQ

Is PFE a buy right now?

Pfizer Inc's current read is a Value / Income setup with 68 confidence over a 6–12 months horizon. Valuation: Fair to Slightly Undervalued. See the full bull and bear case above, or run a live analysis for the exact entry, target and stop.

Is PFE overvalued?

Fair to Slightly Undervalued (valuation score 72/100). Core multiples (P/E, EV/EBITDA, P/FCF) align with large-cap pharma peers; P/B and net margin slightly cheap. However, the 6.8% dividend yield is elevated for the sector and appears to price in significant risk; unsustainable 125.8% payout ratio likely explains the discount. Valuation is attractive for income, but growth visibility and dividend safety are material concerns.

What are the risks of buying PFE?